During therapeutic trials, Plus Therapeutics discovered the standard diagnostic for leptomeningeal cancer was a test from 1904. Recognizing this critical gap, they acquired the advanced CNSide assay, turning a clinical development bottleneck into a synergistic, multi-billion dollar commercial opportunity.
A physician who became a biotech CEO found business school less about profound secrets (like medicine) and more about gaining the language and confidence to effectively collaborate with finance professionals, which proved essential for leading a financing-intensive business.
A non-obvious consequence of effective modern cancer drugs is that patients live longer, allowing more time for cancer cells to metastasize to the central nervous system. The brain's protective blood-brain barrier then ironically shields these new tumors from treatment, creating a growing patient population.
For its leptomeningeal cancer drug, Plus Therapeutics found the FDA receptive to clinical trial endpoints beyond overall survival. The agency was open to "compartmental based endpoints" measuring efficacy within the targeted CNS area—a significant regulatory shift for non-systemic treatments with no established approval pathway.
The company's shift from cell therapy wasn't a failure, but a strategic move. They targeted central nervous system cancers, an area with a massive unmet need demonstrated by virtually no improvement in patient survival for four decades, while other cancer survival rates improved 300%.
Rhenium emits both beta particles (for therapy) and gamma rays (for imaging). This unique property allows Plus Therapeutics to see exactly where the drug goes and calculate the precise radiation dose absorbed by the tumor, effectively making every patient a well-controlled, single-subject study.
By engineering a therapeutic index of 100-to-1, far superior to other radiotherapeutics, Plus's Rayobic can deliver up to 740 gray of radiation in a single dose. This is over ten times the 30-50 gray limit of standard external beam therapy, representing a massive leap in potential efficacy.
Unlike radiotherapeutics with short half-lives requiring local production, Plus Therapeutics' use of Rhenium-186 (90-hour half-life) is a key operational advantage. It allows for centralized manufacturing and a flexible supply chain, enabling shipment across the U.S. and to Europe from a single facility.